NDD2020

Call for Papers

With an emphasis on depressive disorders, schizophrenia, addiction and PTSD, this timely meeting provides a much-needed platform for industry and academic thought leaders to:

- Dive into novel therapeutic approaches for PTSD with Aptinyx, Bionomics, Tonix and MAPS 

- Uncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics and Intra-cellular Therapeutics

- Explore industry approaches for innovative trial design and new methods to modeling the placebo response with Novartis, Otsuka and Yale University

- Hear how pioneering biotechs are spearheading drug development for substance use disorders with Cerevel Therapeutics, Opiant Pharmaceuticals and NIDA

- Learn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda

- Uniting 80+ drug developers from all corners of the world, Neuropsychiatric Drug Development is your opportunity to discuss in depth, how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics.

Prices:

Industry Pricing: Conference + 2 Workshops: USD 4097.0,

Industry Pricing: Conference + 1 Workshop: USD 3498.0,

Industry Pricing: Conference Only: USD 2899.0,

Industry Pricing: Workshop Only: USD 699.0,

Academic: Conference + 2 Workshops: USD 3497.0,

Academic: Conference + 1 Workshop: USD 2998.0,

Academic: Conference Only: USD 2499.0,

Academic: Workshop Only: USD 599.0

Speakers: Gopi Shanker, Novartis Institutes for Biomedical Research, Seth Lederman, CEO and Chairman Tonix Pharmaceuticals, Steve Paul, Karuna Therapeutics, Inc, Kurt Rasmussen, The National Institute on Drug Abuse (NIDA), Patricio O'Donnell, Takeda Pharmaceuticals, Andy Kidd, Aptinyx, Errol De Souza, Bionomics, Phil Skolnick, Opiant, Jill Harkavy Friedman, American Foundation for Suicide Prevention, Nassir Ghaemi, Novartis Institutes for Biomedical Research, Gerard Sanacora, Yale University School of Medicine, Sharon Mates, Intra-Cellular Therapies, Inc., Srikanth Gottipati, Otsuka Pharmaceuticals, David Donabedian, Axial Biotherapeutics, J Randall Owen, Navitor Pharmaceuticals, Gary K. Zammit, Clinilabs Drug Development Corporation, Rick Doblin, Multidisciplinary Association for Psychedelic Studies (MAPS), Christopher Missling, Anavex, Angel Angelov, Neurocrine, Chris Min, Cerevel Therapeutics, Sheldon Preskorn, University of Kansas School of Medicine (UKSM), Al Robichaud, Sage Therapeutics

Time: 08:00 - 16:10